Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04937530
Recruitment Status : Recruiting
First Posted : June 24, 2021
Last Update Posted : June 25, 2021
Sponsor:
Information provided by (Responsible Party):
Retrotope, Inc.

Brief Summary:
This is a randomized, placebo-controlled trial of RT001 in patients with PSP.

Condition or disease Intervention/treatment Phase
Progressive Supranuclear Palsy Drug: RT001 Drug: Placebo Phase 2

Detailed Description:
This is a randomized, placebo-controlled trial of RT001 in patients with PSP to assess the efficacy, safety and tolerability of RT001. Subjects will be randomized to RT001 or placebo and will receive study drug for 48 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Controlled, Phase 2 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Progressive Supranuclear Palsy
Actual Study Start Date : June 23, 2021
Estimated Primary Completion Date : July 30, 2022
Estimated Study Completion Date : August 30, 2022


Arm Intervention/treatment
Experimental: RT001
RT001 960 mg capsule. 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 44 weeks.
Drug: RT001
RT001 8.64 g/d (3 capsules TID) for 1 month followed by 5.76 g/d (3 capsules BID) for an additional 11 months
Other Name: di-deuterated linoleic acid ester

Placebo Comparator: Placebo
Inactive comparator capsule 960 mg (safflower oil). 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 44 weeks.
Drug: Placebo
Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 44 weeks.
Other Name: safflower oil




Primary Outcome Measures :
  1. Change from baseline in the PSPRS-28 at 48 weeks for the RT001 treated group vs placebo-treated group [ Time Frame: 48 weeks ]
    The PSPRS-28 is a clinician-rated instrument to assess disability and severity of PSP. The PSPRS-28 evaluates 28 items in six categories: daily activities (by history), behavior, bulbar, ocular motor, limb motor and gait/midline.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Sign the informed consent form prior to entry into the study
  2. Male or female subject with age 40 years to 80 years at the time of signed consent
  3. Meets the MDS-PSP study group criteria for possible or probable progressive supranuclear palsy with Richardson syndrome (postural instability and falls with vertical ocular motor dysfunction)
  4. Presence of PSP symptoms for less than 4 years
  5. Score of <40 on the PSPRS-28
  6. Ambulatory patients (with or without assistive device - no handheld help) and capable of performing study assessments/evaluations
  7. Subject has an identified, reliable, study partner (e.g., caregiver, family member, social worker, or friend) who can assist in assuring that the subject is able to travel to the required visits.
  8. Willing to provide the necessary blood samples

Exclusion Criteria:

  1. Received treatment with other experimental therapies within the last 30 days prior to the first dose. The last dose of the prior experimental agent must have occurred more than 5 half-lives prior to enrollment in the current trial.
  2. Previously received treatment with RT001
  3. Refusal to discontinue fish oils or other oil-based supplements for the duration of the study (Screening/Baseline till last study procedure completed)
  4. Mini mental state examination (MMSE) score less than 20 at screening
  5. Subject resides at a skilled nursing or dementia care facility, or admission to such a facility is planned during the study period
  6. Evidence of any clinically significant neurological disorder other than PSP in particular CBS
  7. Evidence of a clear and robust benefit from levodopa at the time of screening. Participants are permitted to take levodopa and other Parkinson's medications if the dose had been stable for 60 days prior to screening
  8. The subject has a history of or currently has schizophrenia, schizoaffective disorder or bipolar disorder according to DSM-V or ICD-10 criteria
  9. Subject has had a significant illness or infection requiring medical intervention in the past 30 days
  10. Subject has evidence of any disease or condition (based on either history, physical or laboratory values) that might interfere with the conduct of the study
  11. Is currently receiving active deep brain stimulation (DBS) that cannot be turned off
  12. Any condition with a life expectancy of less than 2 years
  13. Female who is breastfeeding or has a positive pregnancy test
  14. Male participant or female participant of childbearing potential, who is sexually active and unwilling/unable to use a highly effective birth control method throughout the study
  15. Unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's ability to return for visits as scheduled
  16. History, within the last 2 years, of alcohol abuse or physical opioid dependence

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04937530


Contacts
Layout table for location contacts
Contact: Mark G. Midei, MD (650) 437-0700 mark@retrotope.com

Locations
Layout table for location information
Germany
Agaharied Teaching Hospital, University of Munich Recruiting
Munich, MD, Germany, 21111
Contact: Mark G. Midei, MD       mark@retrotope.com   
Sponsors and Collaborators
Retrotope, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Stefan Lorenzl, MD, PhD Ludwig-Maximilians - University of Munich
Layout table for additonal information
Responsible Party: Retrotope, Inc.
ClinicalTrials.gov Identifier: NCT04937530    
Other Study ID Numbers: RT001-013
First Posted: June 24, 2021    Key Record Dates
Last Update Posted: June 25, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Paralysis
Supranuclear Palsy, Progressive
Neurologic Manifestations
Nervous System Diseases
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Ophthalmoplegia
Ocular Motility Disorders
Cranial Nerve Diseases
Tauopathies
Neurodegenerative Diseases
Eye Diseases